Back
Axsome Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
AXSM
Sponsored
U.S. Government Report Alert Tuesday
Discover the Secret Loophole
Buy
68
AXSM
Axsome Therapeutics
Last Price:
90.02
Seasonality Move:
48.72%
7 Day Trial
ALL ACCESS PASS
$
7
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE TradeAxsome Therapeutics Price Quote
$90.02
-0.05 (-0.75%)
(Updated: November 9, 2024 at 5:14 AM ET)
Axsome Therapeutics Key Stats
Buy
68
Axsome Therapeutics (AXSM)
is a Buy
Day range:
$89.13 - $91.37
52-week range:
$55.02 - $98.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
14.63
P/B ratio:
42.03%
Volume:
635.3K
Avg. volume:
410.5K
1-year change:
46.31%
Market cap:
$4.3B
Revenue:
$270.6M
EPS:
$-6.51
How Much Does Axsome Therapeutics Make?
-
How Much Are Axsome Therapeutics's Sales Annually?
AXSM Revenues are $270.6M -
How Much Profit Does Axsome Therapeutics's Make A Year?
AXSM net income is -$239.2M
Is Axsome Therapeutics Growing As A Company?
-
What Is Axsome Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.87% -
What Is Axsome Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Axsome Therapeutics Stock Price Performance
-
Did Axsome Therapeutics Stock Go Up Last Month?
Axsome Therapeutics share price went up by 6.19% last month -
Did AXSM's Share Price Rise Over The Last Year?
AXSM share price rose by 46.31% over the past 1 year
What Is Axsome Therapeutics 52-Week High & Low?
-
What Is Axsome Therapeutics’s 52-Week High Share Price?
Axsome Therapeutics has traded as high as $98.40 over the past 52 weeks -
What Is Axsome Therapeutics’s 52-Week Low Share Price?
Axsome Therapeutics has traded as low as $55.02 over the past 52 weeks
Axsome Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Axsome Therapeutics?
-
How Much Debt Does Axsome Therapeutics Have?
Total long term debt quarterly is $179.3M -
How Much Cash Does Axsome Therapeutics Have?
Cash and short term investments quarterly total is $315.7M -
What Is Axsome Therapeutics’s Book Value Per Share?
Book value per share is 2.15
Is Axsome Therapeutics Cash Flow Positive?
-
What Is AXSM Cash Flow From Operations?
Cash flow from operations (TTM) is -$167.5M -
What Is Axsome Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $46.6M -
What Is Axsome Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$528K
Axsome Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
AXSM return on invested capital is -82.21% -
What Is Axsome Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -53.3% -
What Is AXSM Return On Equity?
ROE is a measure of profitability and is -156.44%
Axsome Therapeutics Earnings Date & Stock Price
-
What Is Axsome Therapeutics's Stock Price Today?
A single share of AXSM can be purchased today for 90.07 -
What Is Axsome Therapeutics’s Stock Symbol?
Axsome Therapeutics trades on the nasdaq under the ticker symbol: AXSM -
When Is Axsome Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Axsome Therapeutics is scheduled on November 12, 2024 -
When Is AXSM's next ex-dividend date?
Axsome Therapeutics's next ex-dividend date is November 10, 2024 -
How To Buy Axsome Therapeutics Stock?
You can buy Axsome Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Axsome Therapeutics Competitors
-
Who Are Axsome Therapeutics's Competitors?
Below is a list of companies who compete with Axsome Therapeutics or are related in some way:
Axsome Therapeutics Dividend Yield
-
What Is AXSM Dividend Yield?
Axsome Therapeutics’s dividend yield currently is 0% -
What Is Axsome Therapeutics’s Payout Ratio?
Axsome Therapeutics’s payout ratio is 0% -
When Did Axsome Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 10, 2024 -
What Is Axsome Therapeutics’s Dividend Per Share?
Axsome Therapeutics pays a dividend of $0.00 per share
Axsome Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -25.84% |
Revenue: | 86.65% | 0.27% |
Analyst Recommendations
Buy Recommendations: | 12 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 125.29 |
Upside from Last Price: | 39.11% |